Back to Search Start Over

Multicentre cohort study of acute cholecystitis management during the COVID-19 pandemic

Authors :
Elías Rodríguez Cuéllar
Javier Martínez Caballero
Juan José Pérez Alegre
Arantxa Villadoniga
María Díaz
David Alias Jiménez
Víctor Vaello Jodra
David Pérez
Monica Galan Martín
Rosario San Román Romanillos
Mariana García Virosta
María de Mar Pardo de Lama
Marcello Di Martino
Jenny Guevara-Martínez
Marta de la Fuente Bartolomé
Roberto Martínez Fernández
Jana Dziakova
María Gutiérrez Samaniego
Cristina Pérez Algar
Luis de Nicolás Navas
Ángela de la Hoz Rodríguez
Lucía González González
Eduardo Ferrero Herrero
Daniel Sánchez López
Javier García-Quijada García
Source :
European Journal of Trauma and Emergency Surgery
Publication Year :
2020

Abstract

Purpose To analyse acute cholecystitis (AC) management during the first pandemic outbreak after the recommendations given by the surgical societies estimating: morbidity, length of hospital stay, mortality and hospital-acquired SARS-CoV-2 infection rate. Methods Multicentre-combined (retrospective–prospective) cohort study with AC patients in the Community of Madrid between 1st March and 30th May 2020. 257 AC patients were involved in 16 public hospital. Multivariant binomial logistic regression (MBLR) was applied to mortality. Results Of COVID-19 patients, 30 were diagnosed at admission and 12 patients were diagnosed during de admission or 30 days after discharge. In non-COVID-19 patients, antibiotic therapy was received in 61.3% of grade I AC and 40.6% of grade II AC. 52.4% of grade III AC were treated with percutaneous drainage (PD). Median hospital stay was 5 [3–8] days, which was higher in the non-surgical treatment group with 7.51 days (p 0.05). In patients with hospital-acquired SARS-CoV-2 infection, 91.7% of grade I–II AC were treated with non-surgical treatment (p = 0.037), with a median hospital stay of 16 [4–21] days and a 18.2% mortality rate (p > 0.05). Hospital-acquired infection risk when hospital stay is > 7 days is OR 4.7, CI 95% (1.3–16.6), p = 0.009. COVID-19 mortality rate was 11.9%, AC severity adjusted OR 5.64 (CI 95% 1.417–22.64). In MBLR analysis, age (OR 1.15, CI 95% 1.02–1.31), SARS-CoV-2 infection (OR 14.49, CI 95% 1.33–157.81), conservative treatment failure (OR 8.2, CI 95% 1.34–50.49) and AC severity were associated with an increased odd of mortality. Conclusion In our population, during COVID-19 pandemic, there was an increase of non-surgical treatment which was accompanied by an increase of conservative treatment failure, morbidity and hospital stay length which may have led to an increased risk hospital-acquired SARS-CoV-2 infection. Age, SARS-CoV-2 infection, AC severity and conservative treatment failure were mortality risk factors.

Details

ISSN :
18639941
Volume :
47
Issue :
3
Database :
OpenAIRE
Journal :
European journal of trauma and emergency surgery : official publication of the European Trauma Society
Accession number :
edsair.doi.dedup.....874b1bc953793ff4805a7121bc7be85c